This paper aims to outline the current knowledge on NO pathway dysfunction in PAD, including recent developments in understanding the role of asymmetric dimethylarginine (ADMA) and dimethylarginine dimethylaminohydrolase (DDAH); it will also explore potential therapeutic strategies based on the manipulation of this pathway. The gene discussed is DDAH1; the disease is peripheral arterial disease.